Our findings that MI-2 administration prevents MALT1-mediated MCPIP1 degradation in vivo and protects mice from LPS-induced inflammation and lung injury, suggests that pharmacological inhibition of MALT1 protease activity by MI-2 may be an effective strategy for preventing/treating sepsis-associated lung injury. This evidence concerns the gene MALT1 and Sepsis.